Driving Innovation in Vaccine Research and Development

At BioNet, our Research and Development (R&D) efforts are at the forefront of vaccine innovation, combining cutting-edge science with a mission to address urgent public health challenges. Our R&D focuses on creating next-generation vaccines using advanced platforms, including recombinant, DNA, and mRNA technologies.

Revolutionizing Vaccine Platforms

Recombinant Vaccines

Leveraging genetically engineered technologies to produce safe and effective vaccines with enhanced immunogenicity and safety profiles.

DNA Vaccines

Developing novel approaches to harness the body’s immune system by directly delivering genetic material to elicit a protective response.

mRNA Vaccines

Utilizing our proprietary “plug-and-play” design to swiftly adapt to emerging diseases and rapidly produce research and GMP grade vaccines.

Targeting
Global Health
Threats

BioNet’s development pipeline focuses on combating respiratory diseases, vector-borne illnesses, and zoonotic infections, with a strong emphasis on re-emerging and pandemic threats. By addressing these critical areas, we aim to deliver innovative vaccines that improve global health outcomes.

Key Achievements and Milestones

Completion of 15+ successful clinical trials validating the safety and efficacy of our Pertussis vaccines.

Rapid development of mRNA vaccine candidates, including pancoronavirus candidate, using state-of-the-art platforms.

Expansion of our pipeline to address
emerging infectious diseases and unmet
medical needs.

Proprietary mRNA Platform


Our unique and flexible mRNA plug-and-play platform is highly adaptable for pandemic preparedness. We have developed multiple candidates against potential threats, leveraging the platform’s ability to quickly respond to emerging pathogens including:

– Avian influenza
– Pandemic influenza
– Combination Flu-CoV-RSV

Our platform enables development of a wide range of vaccines candidates:

– Research lot in 10 days
– GMP lot in 100 days

Clinically Proven Solution


Through the establishment of global and strategic  R&D consortia, our mRNA process development demonstrates effectiveness, safety and adaptability to emerging variants. These collaborative efforts ensure that we stay at the forefront of innovation, continuously improving our methodologies to meet the evolving challenges of public health, and enabling fast trajectories to clinical trials:

Monovalent SARS-CoV-2 (Wuhan):
– Phase 1 Primary immunization in Thailand
– Phase 2 Booster trial in Australia

Bivalent SARS-CoV-2 (Wuhan/Omicron):
– Phase 2 Booster Trial in Australia

Committed to Transforming Global Health

At BioNet, we believe that innovation is the key to a healthier, safer world. Our R&D teams work tirelessly to bring groundbreaking vaccine solutions to market, ensuring access to life-saving immunizations for all.

Join Us in Shaping the Future


BioNet invites collaborators, researchers, and industry leaders to join us in transforming vaccine innovation. Together, we can build a healthier future for generations to come.